β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers

Soumya Tumbath Lingxiang Jiang Xiaoguang Li Taolan Zhang Kashif Rafiq Zahid Ye Zhao Hao Zhou Zhijun Yin Tao Lu Shu Jiang Yaomin Chen Xiang Chen Yang-Xin Fu Xiumei Huang a Department of Radiation Oncology,Indiana University School of Medicine,Indianapolis,IN,USAb Department of Pathology,University of Texas Southwestern Medical Center,Dallas,TX,USAc Department of Biomedical Informatics,Vanderbilt University Medical Center,Nashville,TN,USAd Department of Pharmacology and Toxicology,Indiana University School of Medicine,Indianapolis,IN,USAe Indiana University Melvin and Bren Simon Comprehensive Cancer Center,Indiana University School of Medicine,Indianapolis,IN,USAf Division of public health sciences,Washington University School of Medicine,St. Louis,MO,USAg Indiana University Health Pathology Laboratory,Indiana University School of Medicine,Indianapolis,IN,USAh Department of Computational Biology,St. Jude Children's Research Hospital,Memphis,TN,USA

DOI: https://doi.org/10.1080/2162402x.2024.2363000

2024-06-06

OncoImmunology

Abstract:NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in most solid cancers, emerging as a promising target for tumor-selective killing. β-Lapachone (β-Lap), an NQO1 bioactivatable drug, exhibits significant antitumor effects on NQO1-positive cancer cells by inducing immunogenic cell death (ICD) and enhancing tumor immunogenicity. However, the interaction between β-Lap-mediated antitumor immune responses and neutrophils, novel antigen-presenting cells (APCs), remains unknown. This study demonstrates that β-Lap selectively kills NQO1-positive murine tumor cells by significantly increasing intracellular ROS formation and inducing DNA double strand breaks (DSBs), resulting in DNA damage. Treatment with β-Lap efficiently eradicates immunocompetent murine tumors and significantly increases the infiltration of tumor-associated neutrophils (TANs) into the tumor microenvironment (TME), which plays a crucial role in the drug's therapeutic efficacy. Further, the presence of β-Lap-induced antigen medium leads bone marrow-derived neutrophils (BMNs) to directly kill murine tumor cells, aiding in dendritic cells (DCs) recruitment and significantly enhancing CD8 + T cell proliferation. β-Lap treatment also drives the polarization of TANs toward an antitumor N1 phenotype, characterized by elevated IFN-β expression and reduced TGF-β cytokine expression, along with increased CD95 and CD54 surface markers. β-Lap treatment also induces N1 TAN-mediated T cell cross-priming. The HMGB1/TLR4/MyD88 signaling cascade influences neutrophil infiltration into β-Lap-treated tumors. Blocking this cascade or depleting neutrophil infiltration abolishes the antigen-specific T cell response induced by β-Lap treatment. Overall, this study provides comprehensive insights into the role of tumor-infiltrating neutrophils in the β-Lap-induced antitumor activity against NQO1-positive murine tumors.

oncology,immunology

What problem does this paper attempt to address?

The paper attempts to address the issue of how β-Lapachone (β-Lap) exerts its antitumor effects in NQO1-positive cancers by promoting the recruitment and polarization of tumor-associated neutrophils (TANs). Specifically, the researchers focus on the following aspects: 1. **The effect of β-Lap on NQO1-positive tumor cells**: Investigating whether β-Lap can selectively kill NQO1-positive tumor cells and exploring its mechanisms, including the induction of intracellular reactive oxygen species (ROS) generation and DNA damage. 2. **The effect of β-Lap on TANs in the tumor microenvironment**: Studying whether β-Lap treatment can significantly increase the infiltration of TANs in the tumor microenvironment and exploring the role of these TANs in antitumor immune responses. 3. **Polarization of TANs**: Investigating whether β-Lap can promote the polarization of TANs towards the antitumor N1 phenotype and exploring the key signaling pathways involved in this process, such as the HMGB1/TLR4/MyD88 signaling cascade. 4. **The role of TANs in β-Lap-mediated antitumor immune responses**: Studying the direct cytotoxic effects of TANs on tumor cells after β-Lap treatment, as well as their role in recruiting dendritic cells (DCs) and enhancing CD8+ T cell proliferation. Through these studies, the authors aim to comprehensively understand the antitumor mechanisms of β-Lap in NQO1-positive tumors, particularly the crucial role of TANs in this process.

β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers

Abstract 3851: Beta-lapachone promotes tumor associated neutrophils (TANs) polarized towards anti-tumor (N1) phenotype

NQO1 Targeting Prodrug Triggers Innate Sensing to Overcome Checkpoint Blockade Resistance

β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis

Efficacy of beta-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1

Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy

Augmented Concentration of Isopentyl-Deoxynyboquinone in Tumors Selectively Kills NAD(P)H Quinone Oxidoreductase 1-Positive Cancer Cells through Programmed Necrotic and Apoptotic Mechanisms

Enhanced Chemodynamic Therapy Mediated by a Tumor‐Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer

Synergistic Effect of β-Lapachone and Aminooxyacetic Acid on Central Metabolism in Breast Cancer

An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-induced Programmed Necrosis.

Catalytic Modulation of the Tumor Microenvironment Using Cascade Enzymes for Synergistic Boron Neutron Capture Therapy in the Treatment of Gliomas

Abstract A070: Time-Dependent Oxidation and Aggregation of Vimentin upon Binding by β-lap Induced Immunogenic Cell Death

β-Lapachone induces ferroptosis of colorectal cancer cells via NCOA4-mediated ferritinophagy by activating JNK pathway

Albumin Binding Revitalizes NQO1 Bioactivatable Drugs As Novel Therapeutics for Pancreatic Cancer

Glutathione-Activated NO-/ROS-Generation Nanoparticles to Modulate the Tumor Hypoxic Microenvironment for Enhancing the Effect of HIFU-Combined Chemotherapy

Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma

Lysosome-Oriented, Dual-Stage Ph-Responsive Polymeric Micelles For Beta-Lapachone Delivery

Β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy As Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells

Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery

Mesoporous Bi-Containing Radiosensitizer Loading with DOX to Repolarize Tumor-Associated Macrophages and Elicit Immunogenic Tumor Cell Death to Inhibit Tumor Progression.